Members can apply mass cytometry data analysis in applications including cell identification, detection of clinical biomarkers, cell phenotyping, phosphorylation-induced signaling, and functional readouts of cell-cycle status, proliferation, and apoptosis in human and murine samples.
We are capable of measuring over 40 available channels simultaneously using metal conjugated antibodies. Users can access the Helios mass cytometer and receive expert counseling on basic science and clinical research applications in the fields of immunology, cancer biology, systems biology, and autoimmunity.
The Immune Monitoring Shared Resource offers the following services:
- Counseling for panel design, antibody selection, and antibody conjugation.
- Mass cytometry standardization training for published techniques including antibody titration, data validation, and data analysis workflow.
- Software support and training for the cloud-based data analysis platform Cytobank.
Be sure to contact us well in advance if you are a first-time user of mass cytometry instrumentation.
Publication Acknowledgement Policy
The National Cancer Institute requires that publications acknowledge the Winship Cancer Institute Cancer Center Support Grant (CCSG), and it is tracking compliance. If a Winship Cancer Institute CCSG-supported Shared Resource provided data, designed the study, performed analyses, provided results used in your publication, and/or provided any systems or services that were used for the work that resulted in your publication, please include the following statement in the acknowledgment section of your publication(s):
Research reported in this publication was supported in part by the Immune Monitoring Shared Resource of Winship Cancer Institute of Emory University and NIH/NCI under award number P30CA138292. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
- Professor, Department of Pediatrics
- Emory University School of Medicine
A leading cancer immunology researcher, Dr. Dhodapkar serves as director of the Pediatric Immuno-Oncology Program at the Aflac Cancer and Blood Disorders Center.